.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FG02_Ramucirumab.Ramucirumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FG02_Ramucirumab.Ramucirumab| name: | Ramucirumab |
| ATC code: | L01FG02 | route: | intravenous |
| n-compartments | 2 |
Ramucirumab is a fully human IgG1 monoclonal antibody that targets the vascular endothelial growth factor receptor-2 (VEGFR-2), inhibiting angiogenesis. It is used and approved for the treatment of various advanced cancers, including gastric cancer, non-small cell lung cancer, and colorectal cancer, most often in combination with other chemotherapeutic agents.
Pharmacokinetic parameters reported for adult cancer patients, both sexes, after intravenous infusion as monotherapy or in combination. Parameters are population pharmacokinetics from clinical trials in cancer populations.
O'Brien, L, et al., & Heathman, M (2017). Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. British journal of clinical pharmacology 83(12) 2741–2751. DOI:10.1111/bcp.13403 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28833321
Gao, L, et al., & Abada, P (2021). Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach. Cancer chemotherapy and pharmacology 87(5) 635–645. DOI:10.1007/s00280-020-04223-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33532866
Cao, J, et al., & Li, J (2017). Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. The oncologist 22(6) 638–e56. DOI:10.1634/theoncologist.2017-0137 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28465370